Inclusion Criteria

• Age 18 to 70 years.
• Histologically proven non-Hodgkin's lymphoma
• Relapse after achieving initial remission or failure to achieve initial remission. Patients with residual radiographic abnormalities after primary therapy are eligible if abnormalities are FDG-PET positive. Patients in groups 5 or 6 are eligible for the protocol if they are in first complete remission.

• Eligible patients must have either

  1. transformed lymphoma
  2. mycosis fungoides that is resistant or refractory to therapy
  3. other histological subtypes in patients that do not have adequate cytoreduction to salvage chemotherapy to reach a minimal disease state
  4. patients in 3rd or greater relapse or subsequent remission
  5. patients with aggressive T-cell lymphomas or
  6. other patients with non-Hodgkin's lymphoma felt to have less than a 20% chance of event-free survival with autologous transplant after discussion with the Lymphoma Faculty and the Principal Investigator
• ECOG performance status < or = 2
• Matched related or unrelated donor identified and available. Donor must be a complete match or have only a single allele mismatch.
• Bone marrow biopsy and cytogenetic analysis within 8 weeks of baseline
• Women of child-bearing potential and sexually active males must use an accepted and effective method of birth control.
• Patients must have a pretreatment serum bilirubin < or = 2 x the institutional ULN, a serum creatinine < or = 2 x the institutional ULN and measured or estimated creatinine clearance > 60 cc/min
• Patients must have an EKG within 42 days prior to baseline that shows no significant abnormalities that are suggestive of active cardiac disease.
• Patients must have an echocardiogram or MUGA scan within 42 days of baseline. If the ejection fraction is <40%, the patient will not be eligible.

If the ejection fraction is 40-50%, patients must have an exercise echocardiogram or dobutamine-echo with a normal response to exercise.

• Patients must have a corrected diffusion capacity > or = 50% prior to the autologous transplant and > or = 40% prior to the allogeneic transplant.
• Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.
• Have a related or unrelated HLA identical donor who is in good health and have no contra-indications for donation according to standard of care criteria.

Exclusion Criteria

• Patients with known allergy to etoposide or a history of Grade 3 hemorrhagic cystitis with cyclophosphamide.
• Pregnant or breast-feeding women due to the known birth defects association with the treatments used in this study.
• Patients known to be human immunodeficiency virus (HIV)-positive because the concern for opportunistic infection and hematologic reserve are considered to be significantly greater in this population. The antibody test for HIV must be performed within 42 days of baseline.
• No chemotherapy should be administered within 2 weeks of the initiation of protocol therapy.
• No prior malignancy is allowed except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or other cancer for which the patients has been disease-free for five years.
• Patients with active infection requiring oral or intravenous antibiotics.
• No prior autologous or allogeneic hematopoietic cell transplantation.
• No prior radioimmunotherapy